Palvella Therapeutics Reports Strong Phase 3 & 2 Data for QTORIN™ Rapamycin in Rare Vascular Malformations

summarizeSummary

Palvella Therapeutics announced new, highly positive clinical data for QTORIN™ rapamycin from its Phase 3 SELVA and Phase 2 TOIVA studies, reinforcing its potential as a first-in-disease therapy for rare vascular malformations and setting clear regulatory timelines.

check_boxKey Events

• Phase 3 SELVA Study Data

  QTORIN™ rapamycin demonstrated 100% 'Much Improved' or 'Very Much Improved' in a key pediatric cohort and significant improvement in severe symptoms like leaking/bleeding for microcystic lymphatic malformations.

• Phase 2 TOIVA Study Data

  The study showed statistically significant improvements in both height and appearance of cutaneous venous malformations, with increasing clinical response observed with longer duration of therapy.

• High Patient Satisfaction

  100% of SELVA participants who completed the efficacy evaluation period were at least somewhat satisfied with QTORIN™ rapamycin, with 84% reporting extremely satisfied, very satisfied, or satisfied.

• Regulatory Pathway Confirmed

  Palvella plans to submit an NDA for mLM in the second half of 2026 (with potential approval in H1 2027) and initiate a Phase 3 trial for cVM in the second half of 2026, targeting first-in-disease approvals.

auto_awesomeAnalysis

This filing details highly positive clinical data from both the Phase 3 SELVA study for microcystic lymphatic malformations (mLM) and the Phase 2 TOIVA study for cutaneous venous malformations (cVM). The strong efficacy and patient satisfaction data, particularly for mLM in younger patients and for severe symptoms like leaking/bleeding, significantly de-risk QTORIN™ rapamycin as a potential first-in-disease therapy. The company's plans to file an NDA for mLM in the second half of 2026 and initiate a Phase 3 trial for cVM in the same period provide a clear path to market for these indications, which currently lack FDA-approved treatments.